Updates are available Correction dated 2019-10-18
Click to view Correction: https://doi.org/10.1186/s12872-019-1195-z
-
Authors
Lutschinger, Leon L.
Rigopoulos, Angelos G.
Schlattmann, Peter
Matiakis, Marios
Sedding, Daniel
Schulze, Paul Christian
Noutsias, Michel https://orcid.org/0000-0002-9066-5262
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (Sonderforschungsbereich Transregio 19 “Inflammatory Cardiomyopathy” (SFB TR19; TB2)
University Hospital Giessen and Marburg Foundation (UKGM 10/2009)
- License Information
-
More Information
Article History
Received: 16 May 2019
Accepted: 25 August 2019
First Online: 2 September 2019
Change Date: 18 October 2019
Change Type: Correction
Change Details: After publication of the original article [1], we were notified that an author’s name is not complete.
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: MN has been consultant to the IKDT (Institute for Cardiac Diagnosis and Therapy GmbH, Berlin) 2004–2008, and has received honoraria for presentations and/or participated in advisory boards from AstraZeneca, Bayer, Fresenius, Miltenyi Biotech, Novartis, Pfizer and Zoll. AGR has received honoraria for presentations from Astra-Zeneca.
